Key Highlights

• Shares closed at $2.30, down more than 21% on June 24, approaching a 52-week low of $4.20 established just days prior.

• Veraxa Biotech recently listed on Nasdaq and has declined substantially from its debut levels.

• The stock reflects a typical post-listing pattern for small foreign private issuers with limited US institutional sponsorship.

• No negative clinical or regulatory announcement was identified on June 24.

Veraxa Biotech (NASDAQ:VRXA) closed at $2.30 on June 24, falling more than 21% as the post-IPO repricing that has characterized the stock since its Nasdaq debut continued to accelerate.

The company is a clinical-stage biopharmaceutical firm that recently listed on Nasdaq. It has declined substantially from its initial trading levels, a pattern consistent with small foreign private issuers that list on US exchanges without the benefit of significant institutional sponsorship or pre-IPO anchor demand from large fund managers.

Thin liquidity amplifies each session's price moves. With limited float and minimal institutional coverage, even modest selling pressure can drive disproportionately large percentage declines, as the absence of institutional buyers at key price levels creates gaps in the order book.

No negative clinical trial result, regulatory action, or corporate announcement was identified on June 24. The stock's proximity to its 52-week low reflects structural post-listing dynamics rather than any fundamental deterioration in the pipeline.